FTC puts conditions on GSK/Novartis consumer JV


The US Federal Trade Commission has voted to approve UK pharma giant GlaxoSmithKline’s proposed acquisition…

Dr Reddy's LaboratoriesGlaxoSmithKlineHabitrolMergers & AcquisitionsNicodermNovartisPharmaceuticalRegulationUSAVaccines

CSL buys Novartis’ influenza vaccines business for $275 million

CSL buys Novartis’ influenza vaccines business for $275 million


Swiss pharma major Novartis has agreed to divest its influenza vaccines business to Australia’s CSL…

Anti-viralsbioCSLCSL LimitedFinancialMergers & AcquisitionsNovartisPharmaceuticalVaccines

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly


In what looks like a significant restructuring of company focuses, Swiss drug major Novartis and UK peer…

Eli LillyGlaxoSmithKlineMergers & AcquisitionsNovartisPharmaceuticalVaccines

Novartis completes buy of 85% stake in Chinese vaccine maker Tianyuan


Swiss drug major Novartis (NOVN: VX) said this morning that it has now completed the transaction to acquire…

Asia-PacificMergers & AcquisitionsNovartisPharmaceuticalTianyuanVaccines

Novartis to buy Sanofi-Aventis’ 49% stake in Chiron Behring JV for $22.4 million


Aiming to resolve a long-running dispute relating to the rabies vaccine Rabipur, French drug major Sanofi-Aventis’…

Asia-PacificChiron BehringMergers & AcquisitionsNovartisPharmaceuticalRabipurSanofi-AventisVaccines

Talecris teams up with Novartis to market rabies products; law firms investigate proposed buy by Grifols


USA-based Talecris Biotherapeutics has entered into a co-promotion agreement with the vaccines unit of…

GrifolsLicensingMergers & AcquisitionsNovartisPharmaceuticalTalecrisVaccines

Novartis makes another foray into China, buying Zheijian Tianyuan for $125 million


Just a day after revealing a $1 billion-plus investment in China for R&D (The Pharma Letter November…

Asia-PacificGeneralMergers & AcquisitionsNovartisPharmaceuticalVaccines



Back to top